World High Life PLC, (AQSE:LIFE, OTCQB:WRHLF) the AQSE and OTCQB listed investment company, is pleased to provide an update on the progress of its wholly owned subsidiary, Love Hemp, during the global Covid-19 pandemic.

Love Hemp is passionate about creating the UK’s leading range of trusted CBD products, with new product development at the heart of the brand. Love Hemp was the first company to produce functional spring water in the UK infused with CBD. Oils, sprays, vapes, chocolate, jelly domes and beauty products including its innovative CBD infused face mask and body salves have all followed. In response to current challenges, Love Hemp has shifted its focus, building on the opportunity to achieve stronger online sales, achieving a 39% increase month-on-month since January 2020, whilst expanding its offerings to meet consumer demand.


Corporate Highlights

  • The Love Hemp brand (www.love-hemp.com) has increased online sales by 39% month over month since January 2020
  • The brand has secured a number of notable listings with leading retailers including Boots, to complement its existing listings with Ocado, Holland and Barrett and Sainsbury’s
  • According to Alliance Healthcare, the UK’s leading distributor to Pharmacies and Independent Retailers, the Love Hemp brand is now its best-selling CBD brand
  • The brand is in negotiations with some of the UKs’ largest retailers for multiple new product listings from September 2020
  • To support growing demand and sales, Love Hemp’s secondary online retailer, CBDOilsUK (www.cbdoilsuk.com), is expanding its product portfolio with three new brands and a renewed web presence in the near future
  • LH Botanicals (www.lhbotanicals.com), Love Hemp’s CBD wholesale production business, is adding production capacity and new product lines with the acquisition of new machines

Having secured a number of notable listings with leading retailers including Boots, Ocado, Holland and Barrett and Sainsbury’s, as well as being recognized on the list of Best CBD Oil Brands in the UK by the Evening Standard in August 2019, Love Hemp also won the best CBD Brand in The Beauty Shortlist Awards 2020.

New product development is at the heart of the business, with Love Hemp Immune launching in April 2020, more than six-months ahead of schedule, highlighting the brand’s ability to be flexible and agile, whilst responding to consumer needs amidst the current circumstances. There is also a range of new products in development ranging from confectionary to drinks, oils and sprays. Brand renewal work carried out by external marketing partners, Propaganda, will be live in retail stores and online from October 2020.

Additionally, the company’s online retailer, CBDOilsUK, is expanding its product portfolio with the launch of three brands within the next two months, whilst its wholesale production unit, LH Botanicals, is committed to fully supporting customers through this challenging time and has increased production capacity with the acquisition of new capsule and bath bomb production machines.

Tony Calamita, CEO at Love Hemp commented: “There’s no question that the challenges businesses across the world are facing currently are unique. Whilst bricks and mortar stores have either closed or experienced less foot traffic and reduced hours, it has highlighted the need for us to have a robust online presence in order to keep people engaged with our brands and products. We have expanded our online offerings and are committed to continuing to provide the best experience for our customers, so they are able to continue to purchase and engage with us in an efficient way, with minimal disruption. Fortunately, consumer demand for our products is growing and we have adapted, thanks to a great team effort, to be able to grow the business under new circumstances, expanding our e-commerce presence and education marketing, which will be the foundations of our model going forward.”

For further information please contact:

David Stadnyk

Founder & CEO

World High Life PLC

+44 (0) 7926 397 675

info@worldhighlife.uk

AQSE Corporate Adviser

Mark Anwyl/Allie Feuerlein

Peterhouse Capital Limited

+44 (0) 20 7469 0930

ma@peterhousecap.com

af@peterhousecap.com
Financial PR

Camilla Horsfall/Megan Ray

Blytheweigh

+44 (0) 20 7138 3224

Camilla.horsfall@blytheweigh.com

Megan.Ray@blytheweigh.com
For more information on World High Life please visit: www.worldhighlife.uk

Market Abuse Regulation (MAR) Disclosure

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com

Source

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less